The administration of 1.0 mg SDZ 210-086, an orally acting muscarinic agonist, shortened rapid-eye movement (REM) latency, increased REM percent of sleep period time and the total duration of REM sleep, and decreased slow-wave sleep in 12 healthy male subjects. The administration of 0.5 mg SDZ 210-086 had no statistically significant effect on sleep variables. Although the tonic components of REM sleep (REM duration, the REM percent of sleep period time) were increased, (Sitaram et al. 1976 (Sitaram et al. , 1977 Berger et al. 1983) , two cholinesterase inhibitors, and muscarinic agonists such as arecoline , RS-86 (Spiegel, 1984; Riemann et al. 1988) , and pilocarpine (Berkowitz et al. 1990 ) shortened REM latency in normal volunteers.
REM density percent (total) was significantly decreased due to the prolongation of total REM duration (in minutes) and a parallel reduction of the total number of eye movements. This finding is in contrast to studies using other cholinomimetics (i.e., physostigmine, arecoline, and RS 86) and may implicate different generating systems of phasic and tonic REM sleep components. fNeuropsychopharmacology 9:225-232, 1993J
Intracerebral injection of cholinergic agonists into the pontinoreticular formation in animals induced REM sleep (Hobson et al. 1986) . Results from animal studies support the hypothesis that REM sleep is promoted by cholinergic cells located mainly in the pontinoreticular formation which show increased activity during REM sleep and that REM sleep is inhibited by nor adrenergic and serotonergic neurons located in the locus ceruleus and in the raphe nuclei respectively, which show de creased activity during this sleep stage (Hobson et al. 1975 (Hobson et al. , 1986 . Little is known, however, about the specifIc mechanisms generating the phasic or tonic components of REM sleep. Data on animals indicate (Velazquez Moctezuma et al. 1989 ) that the M1 receptor is involved in the de synchronization of the electroen cephalogram (EEG), whereas the M2 receptors are responsible for the generation of muscle atonia. Accord ing to this study, nicotine receptors seem to be involved in the generation of pontogeniculooccipital (PGO) waves and, therefore, may play a role in the genera tion of phasic events such as eye movements (Velaz quez-Moctezuma et al. 1990 ).
Studying the effects of cholinergic agonists on REM sleep regulation is of special interest in research on depression and other psychiatric disorders because the 0893-133X/93/$6.00 effects of cholinergic agonists on sleep parameters in healthy volunteers mimic some of the sleep abnormal ities that are characteristic of depression, such as short ened REM latency, prolonged duration and heightened density of the frrst REM period, and reduced slow-wave sleep (SWS) activity . Some of the ii.ndings obtained can be interpreted within the frame work of the "cholinergic-adrenergic" hypothesis of de pression proposed by Janowsky and coworkers (1972) that postulates an imbalance between central nervous cholinergic and noradrenergic transmitter systems un derlying mania and depression. Rapid-eye movement sleep abnormalities in depression could thus be inter preted as indirect evidence of a muscarinic supersensi tivity in affective disorders.
Orally acting cholinergic agonists (e. g. , RS 86) are particularly suitable for testing the cholinergic regula tion of REM sleep (Berger et al. 1989) , and, therefore, newly available putative cholinergic substances should be tested for their central nervous activity in man. The aim of the present study was to test the effect of the compound SOZ 210-086 on sleep and mood of healthy volunteers. In animal studies, the dioxolan analogue
spiro(4.5)decane), was shown to be a specmc muscarinic agonist lacking nicotinic as well as acetylcholinester ase inhibitory activity OM Palacios unpublished data).
In animal studies, SOZ 210-086 was shown to have properties similar to those of RS 86 (Palacios et al. 1986 Only subjects who were free of medical and psychiatric disorders, had no family history of psychiatric dis orders, and whose regular sleep-wake cycle was simi lar to the lights-out (11 PM) and lights-on (7 AM) schedule in our laboratory were included. All subjects received detailed information about the experimental procedures and possible side effects of the drug and gave their writ ten consent. The research protocol was approved by the university ethics committee.
Mood Assessment
Before retiring and after waking up in the morning, sub jects completed an adjective checklist (AMS) (vonZers sen 1986) to assess mood.
Sleep
Sleep was recorded between lights out (11:00 PM) and lights on (7:00 AM) by means of standard procedures. Horizontal EOG, submental EMG, and EEG ( = C3-A2, C4-A1) were recorded at a paper speed of 10 mm/sec. 6) REM density for each REM period and for the whole night (REM density is defined as the ratio of 3-second miniepochs including eye movements to the total number of 3-second mini epochs per REM period x 100%).
7) REM sleep (in minutes)
: that is, the total duration of REM sleep in minutes for the whole night and for each single REM period.
8) Duration of each non-REM interval (in minutes) for
the whole night.
Statistical Analysis
For descriptive statistics, means ± standard deviation (SO) were calculated. In a frrst step of the analysis, the two placebo nights were compared. As there were significant diff erences between the two placebo nights (see results) that may have been due to carryover effects in night 4, only the frrst placebo night was compared to the drug nights. An analysis of variance (ANOV A) with the factor-repeated measurement was calculated for all relevant sleep variables for the placebo night, the D.5-mg night, and the 1.0-mg night. The ANOVA was corrected according to the method of Greenhouse
Geisser. For ANOV As with a p value < .10, two-tailed
I·tests were calculated to determine differences between the placebo night and the two drug nights. For all cal cul ations, the level of significance was set at 5% (two tailed).
RESULTS
In the first step of the analysis, the two placebo nights (n i ght 2 cent of SPT, total REM density percent, and the total number of eye movements during the whole night were significantly decreased on night 4 compared with night 2. There was also a strong statistical trend toward a de crease of SWS percent of SPT on night 4. As these differ- 
Effects of SDZ 210-086 on Mood and Safety Data
No statistically signifIcant influence of 0.5 mg or 1.0 mg SDZ 210-086 was observed on well-being compared to placebo. There were no signifIcant changes in labora tory values after the study. No adverse effects occurred.
There was no evidence of a change in blood pressure or ventricular rate after administration of 0.5 mg or 1.0 mg SDZ 210-086 compared to placebo.
total REM sleep duration and REM percent of SPT.
Furthermore, 1.0 mg SDZ 210-086 signifIcantly re duced SWS. The shortening of REM latency under the 1.0-mg dose of SDZ 210-086 is in line with comparable studies using physostigmine (Sitaram et al. 1976 (Sitaram et al. , 1977 Berger et al. 1983) , galanthamine (Riemann et al. unpublished data), arecoline (Sitaram et al. 1978a (Sitaram et al. , 1978b , and RS 86 (Spiegel 1984; Riemann et al. 1988 ) in healthy sub
jects. An increase of REM percent of SPT was also ob served under cholinergic stimulation with 1.5 mg RS 86 in healthy probands (Riemann et al. 1988 hours vs. 4 to 6 hours for RS 86; see Palacios et al. 1986 ).
Comparable to RS 86, the frrst non-REM period ( = REM latency) and the second non-REM period were short ened, leading to a shift of the fIrst REM-non-REM cy pilocarpine (Berkowitz et al. 1990) , and RS 86 (Spiegel 1984; Riemann et al. 1988 ), no effect on SWS was found with arecoline (Sitaram et al. 1978a (Sitaram et al. , 1978b or SDZ ENA 713 (Holsboer-Trachsler et al. 1993) . The amount of SWS in the present sample was rather low compared with other studies, especially in comparison to our study with RS 86 (Riemann et al. 1988 ). Because there was no age difference between the samples (RS 86 study: mean age 41.8 ± 15.6 years; SDZ 210-086 study: mean age 39.7 ± 10.8 years), age may not account for the low amount of SWS found in the present study. Most prob ably the low amount of SWS may have been due to a selection bias in this relatively small sample.
Although the effect of cholinomimetic drugs on REM latency is well documented in healthy subjects as well as in depressed patients (Gillin et al. 1991) , only two cholinergic compounds increase REM density in normal subjects. The administration of physostigmine (Sitaram et al. 1976 (Sitaram et al. , 1977 , arecoline (Sitaram et al. 1978a (Sitaram et al. , 1978b , pilocarpine (Berkowitz et al. 1990 ), and i.e., the total number of eye movements were not stimu lated. There was a tendency toward a decrease in the total number of eye movements, which failed, however, to reach significance (ANOV A, P < .11). in the pathogenesis of psychiatric disorders. Unfortu nately, in another independent tolerance study, SDZ
